True. Anavex is simply looking for a gut biome biomarker of response.

Weak rebuttal...

For an "armchair scientist" like myself, lots of interesting interconnections between sigma science and various "hot topics". The various microbiomes present in our bodies among them.

I hope Anavex adds back access to all the raw presentation materials. Some of us geeks like to read that stuff.

The question was, has Anavex read "Spirit of the Coast" science updates NOT read this message board.

Anavex gives zero shitts about this message board, there is NO competitive intelligence to learn from a retail chat board relevant to the operations of Anavex.

Inference = "a conclusion reached on the basis of evidence and reasoning"

Based upon many different and varied pieces of evidence and academic trends in sigmar1 modulation and positive trends from Anavex human trials, yes, one can infer the small molecule drug blarcamesine is being referenced.

From a company watching standpoint the other clues are the recent additions to staff.

Guess they could have used Silicon Valley Bank again, but...whoops that capital provider went tits up.

Yes... and more analysis from the other trials too.

However plans change and those plans are driven by the CEO's larger game plan and may not jive with shorter term retail investor whims.

Ya'll get so worked up about the unknown that biotech definitely isn't a suitable investment for most here.

2 comments stand out: "The changing therapeutic landscape" and "There are really interesting small molecules directed at disease modification" that could refer to the adding the small molecule blarcamesine to the changing "drug development pipeline".

To speculate those comments are about Anavex is exactly that, speculation, but could very well be true.

I mostly agree. I believe the CEO has determined the best course of action is to prepare a total analysis inclusive of "other endpoints" in addition to the Top Line Results in order to gain an "out chance accelerated approval" making the delay well worth the wait.
Or "a very well defined P3 Precision Medicine trial follow-up." Which is also "a very good outcome of a P2b trial!" similar to your more pessimistic quasi long view.

I'm not in the apologist camp, and I do understand investor frustration when timing doesn't go as planned, particularly when the timing was from the CEO in the first place. However plans change and those plans of driven by the CEO's larger game plan and may not jive with shorter term retail investor whims.

The more data with confirming analysis, the more likely a NDA will garner accelerated approval, so I wait and trust the CEO's plan will work better than a rushed alternative.

"The market" has lost faith on equity as an asset class and biotech in particular since 2021 more than losing patience specifically on $AVXL.

Retail may be losing patience but others are adding per last institutional holding report, now who and why are adding is up for discussion, but in aggregate it has increased.

I am oh so humble to the market.
It's kick me off my high horse many times.

Well...actually he did give away quite a few cheap shares, but given the financing agreements in place, the CEO did very with the well timing and size of the offering.

One of his key jobs is to keep the coffers full as shareholder friendly as the market will bear.

Re-read your last sentence and remember retail is along for the ride.

Dr.M's best interests are your best interests (someone calculate Dr.M's "all in" with options fully exercised, e.g. in the event of a buyout) and in his opinion I'm sure he thinks he's doing what is right to to increase shareholder value.

Makes me feel alive to take risks... Wheeee!

If it wasn't for $AVXL I'd be adjusting short term fixed income positions, and that's boring as hell, even with the historic interest rate volatility.

Make sure you're managing cash wisely folks.

Relax... also, Blackrock and State street are mindless indexes there is no secret information to be shared.

Proxy is coming up soon for the annual meeting. Please VOTE.

Sounds to me like the daily grind reading social media FUD is warping your biotech investing logic. To me it's forward progress without failure that matters, not speed or meeting artificial timelines subject to outside factors, and thus far the painfully slow movement is going in the right direction. This is particularly relevant when there has been an upswing in academic publications and the emergence of Sigma 1R competitors recently.

I've been here since 2015 and have followed the scientific backstory of S1R, so I think your disappointment "waiting more than 1 year" quite hillarious.

Trainguy1 on ST will probably be creating a list of grievances for you to join.

Thus far compensation for Dr.M's "achievements" have been stock options and in the early days were related to structural and capital improvements for the company like the uplist to the NASDAQ. Other awards were for completing predetermined by the board milestones such as full enrollment and I'm sure there will be many more awards for his accomplishments.

Impatience plays a role, along with the emotions that come with crappy technicals and a equity bear market can test many longs.

There are big bets on both sides on $AVXL story. It's what keeps it interesting.

LOL, Yep, read that on the interwebs.

Buddy if this was the case I'd be in Australia bribing doctors to prescribe.

I had a full Bloomberg terminal at my fingertips for 20 years and when I semi-retired in 2013 I realized how much I missed it.

I've commented to you in the past I liked the Refinitiv data. Thanks.

Are the holdings of insurance companies, pension funds, hedge funds and family offices as a percentage total aggregate institutional ownership sortable?

Since you're cherry picking data, did you conveniently forget to provide a summary of all the other firms with over $100 million assets under management that are required to file13f not categized as an index fund?

Are the holdings of insurance companies, pension funds, hedge funds and family offices not important when discussing total aggregate institutional ownership?

I'm in the WGT (we got this) camp for Rett.

My bad attempt at humor from the SVB event.

If Rett fails most will flee faster than Silicon Valley Bank depositors.

ARRGGG TAXES is currently a trigger word. LOL!!! Yes, taxes too are a factor.

There is no advantage to exercise early unless there was a plan to sell most or all of the acquired position, and I don't think that's in the CEO's plan to sell. When his time comes to sell, I would guess it would be via prospectus as an existing shareholder at a stock offering well into the future.
Also, with cash actually earning a real return these days it's a waste of money over the time period.

Gotcha, there is definitely a lot learn about amyloid, tau and alpha synuclein and their relationships to various disease states.

You went deeper that the simple point I was making in that alpha synuclein is thought to be a primary factor in PD, PDD, and Lewy Body Dementia. I wanted to mention this particularly with the current focus on only Alzheimer's disease and amyloid.

Proving an upstream mechanism of action that may help multiple seemingly different indications is a big claim, and that will require big evidence and well designed studies.

Correction to an on an earlier comment you made, alpha synuclein not amyloid is thought to contribute to Parkinson's disease .

I personally never set a time frame for $AVXL, as long as there is forward progress without a trial failure remains the strategy.

$8.55'ish is now support, $9 is resistance based on the fact $9 was once a support. A move above $9 and hold can nullify much of this macro market noise.

In many ways, I am an accidental multi-millionaire, but of course I don't tell my wife that. It's all smarts baby, all smarts. LOL

The PR that piqued my interest:

https://www.globenewswire.com/news-release/2015/01/06/695206/10114205/en/Anavex-Encouraged-by-Scientific-Data-Confirming-Sigma-1-Receptor-s-Beneficial-Direct-Interaction-With-Cannabinoid-Receptor.html

I haven't given up on the theory and mabe after cannabis removal from the controlled substance act scientist will deliver the scientific proof.

Dementia regardless of the cause is horrible. The caretaker experience shook me to my core.

Our proven best course of action is diet and exercise. Hopefully in a post blarcamesine approval world the key will also be in getting evaluated early to start treatment.

The side effect profile of trofinetide will greatly limit it's adoption.

I try to be supportive of the Rett community and have tried to take the high road on the topic, but trofinetide is poo poo.

ihub in general is basically a cesspool for OTC traders to swim in.
$AVXL is that 1 out of 100 stocks that ever climb out of it.

If it wasn't the pot stock capitalization boom, which I played like a fiddle, and its relationship with the OTC exchange, I may have never found $AVXL.

Rett first has always been the plan to establish how the upstream S1R MOA operates using a genetic disease where the cause is known.

Back in 2015, when I established my first position (sub $1), I was deep into a dementia caretaker role for my dad (Lewy Body Dementia, alpha synuclein) and didn't understand the rational to focus on rare diseases. Flash forward to 2023 and we now understand the method to the madness in the high value of rare disease drug approvals.

Where things get weird for me is what happens to rare disease drug pricing when it's approved for a large indication like AD? I assume the price drops for those with the rare disease indications too.

Also, some of us have been able to use that time to accumulate as the science, both academic and clinical, have advanced.

I do see his point, but it's rearview mirror speculation, smart money looks forward.

The Anavex FB group shares the important stuff here and on Stocktwits.

Different personalities like different forums.